Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1994-02-04
1999-07-06
Scheiner, Toni R.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241451, 4241581, 5303873, 53038823, 5303892, A61K 39395, C07K 1624
Patent
active
059194529
ABSTRACT:
Treatment of tumor necrosis factor, TNF, mediated pathologies is provided by administering anti-TNF compounds, such as anti-TNF antibodies and anti-TNF peptides, which compounds are specific for tumor necrosis factor-.alpha. (TNF.alpha.) or tumor necrosis factor-.beta. (TNF.beta.) and which are useful for in vivo therapy or diagnosis of TNF.alpha.-mediated pathologies and conditions, wherein the anti-TNF compound is selected from the group consisting of at least one of an immunoglobulin variable region, a fragment of a TNF receptor and an anti-TNF peptide, such as a structural analog of a anti-TNF antibody fragment or a TNF receptor fragment.
REFERENCES:
patent: 4603106 (1986-07-01), Cerami et al.
patent: 4822776 (1989-04-01), Cerami et al.
patent: 5183657 (1993-02-01), Buurman et al.
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5672347 (1997-09-01), Aggarwal et al.
patent: 5750105 (1998-05-01), Newman et al.
Shalaby, M.R. et al. Transplantation. 47:1057-1061, Jun. 1989.
Natanson, C. et al. Annals of Internal Medicine. 120(9):771-783, May 1994.
Sun et al., Journal of Clinical Investigation, vol. 81:1328-1331, "Bowel Necrosis Induced by Tumor Necrosis Factor in Rats Is Mediated by Platelet-activating Factor", May 1988.
Murch et al., Gut, vol.: 32:913-917, "Serum concentrations of Tumour Necrosis Factor alpha in Childhood Chronic Inflammatory Bowel Disease", 1991.
Derkx et al., The Lancet, vol. 342:173-174, Tumour-necrosis-factor antibody treatement In Crogn's disease, Jul. 17, 1993.
Rademacher et al., Seminars in Immunopathology, vol. 10:231-249, "Role of IgG Glycoforms in the Pathogenesis of Rheumatoid Arthritis", 1988.
Lichtenstein et al., Current Opinions in Gastroenterology, vol. 8(4):655-662, "Clinical Advances in Inflammatory Bowel Disease", 1992.
Beutler, B. et al., "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," Nature, 316:552-554 (1985).
Beutler, B. et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," Science, 229:869-871 (1985).
Morrison, Sherie L., "Transfectomas Provide Novel Chimeric Antibodies," Science, 229:1202-1207 (1985).
Brennan, F.M. et al. The Lancet. 2(8657):244-247, Jul. 1989.
Moller, A. et al. Cytokine. 2(3):162-169, May 1990.
Echtenacher, Bernd et al., "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis," J. of Immunology, 145(11):3762-3766 (1990).
Smith, Craig R., "Human and Chimeric Antibodies to LPS and TNF," Abstract, Endotoxemia & Sepsis Conference (1991).
Bodmer, Mark, "Humanized Antibodies for Anti-TNF Therapy," Abstract, Endotoxemia & Sepsis Conference (1991).
Grau GE et al Science 237: 1210-1212, 1987.
Morrison SL Hospital Practice pp. 65-80, Oct. 15, 1987.
Piguet PF et al J Exp Med 166:1280-1289, 1987.
Piguet DF et al J Exp Med 170:655-663, 1989.
Herve, P. et al., "Monoclonal Anti TNF .alpha. Antibody for the Treatment of Severe Acute GvHD in Humans," Abstract 3.25, Lymphoma Res. 9:591 (1990).
Silva, Ayona T. et al., "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor-.alpha. in Experimental Gram-Negative Shock," J. of Infectious Diseases, 162:421-427 (1990).
Opal, Steven M. et al., "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with Pseudomonas aeruginosa," J. of Infectious diseases, 161:1148-1152 (1990).
Tavernier, Jan et al., "Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis," J. Mol. Biol., 211:493-501 (1990).
Lucas, R. et al., "Generation and characterization of a neutralizing rat anti-rm TNF-.alpha. monoclonal antibody," Immunology, 71:218-223 (1990).
Hinshaw, L.B. et al., "Survival of Primates in LD.sub.100 Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF.alpha.)," Circulatory Shock, 30:279-292 (1990).
Nophar, Yaron et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," The EMBO Journal, 9(10):3269-3278 (1990).
Engelmann, Hartmut et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," J. of Bio. Chem., 265(3):1531-1536 (1990).
Verhoef, J. and Torensma, R., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," Eur. J. Clin. Microbiol. Dis., 9(4):247-250 (1990).
Loetscher, Hansruedi et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," Cell, 61:351-359 (1990).
Schall, Thomas J. et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," Cell, 61:361-370 (1990).
Akama, Hideto et al., "Mononuclear Cells Enhance Prostaglandin E.sub.2 Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor .alpha.," Biochemical and Biophysical Research Comm., 168(2):857-862 (1990).
Exley, A.R. et al., "Monoclonal antibody to TNF in severe septic shock," The Lancet, 335:1275-1277 (1990).
Moller, Achim et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor .alpha.: In Vitro and In Vivo Application," Cytokine, 2(3):162-169 (1990).
Ruddle, Nancy H. et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," J. Exp. Med., 172:1193-1200 (1990).
Galloway, Cynthia J. et al., "Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity," J. of Immunological Methods, 140:37-43 (1991).
Waldmann, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy," Science, 252:1657-1662 (1991).
Pennington, James, "TNF: Therapeutic Target in Patients with Sepsis," ASM News, 58(9):479-482 (1992).
Harris, William J. and Emery, Steven, "Therapeutic antibodies--the coming of age," TIBTECH, 11:42-44 (1993).
Parrillo, Joseph E., "Pathogenetic Mechanisms of Septic Shock," N.E. Journal of Medicine, 328(20):1471-1477 (1993).
Aggarwal, Bharat B. et al., "Human Tumor Necrosis Factor Production, Purification and Characterization," J. of Biol. Chem., 260(4):2345-2354 (1985).
Liang, Chi-Ming et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," Biochem. & Biophy. Res. Comm., 137(2):847-854 (1986).
Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," J. of Immun. Methods, 96:57-62 (1987).
Piguet, Pierre-Francois et al., "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," J. Exp. Med., 166:1280-1289 (1987).
Meager, Anthony et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," Hybridoma, 6(3):305-311 (1987).
Fendly, Brian M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," Hybridoma, 6(4):359-370 (1987).
Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," Hybridoma, 6(5):489-507 (1987).
Tracey, Kevin J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," Nature, 330:662-664 (1987).
Nagai, M. et al., "Antibody to tumor necrosis factor (TNF) reduces endotoxin fever," Experientia, 44:606-607 (1988).
Shimamoto, Yoshinori et al., "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," Immunology Letters, 17:311-318 (1988).
Collins, M.S. et al., "Immunoprophylaxis of Polymicrobic Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of Pseudomonas aeruginosa," Abstract E-63, Abstracts of Annual Meeting 1989.
Exley, A.R. et al., "M
Dadonna Peter
Ghrayeb John
Knight David
Le Junming
Seigal Scott
Centocor, Inc.
Johnson Nancy A.
New York University
Scheiner Toni R.
LandOfFree
Methods of treating TNF.alpha.-mediated disease using chimeric a does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating TNF.alpha.-mediated disease using chimeric a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating TNF.alpha.-mediated disease using chimeric a will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-897235